Recently, two classes of migraine-specific drugs have been introduced, which either directly target the neuropeptide calcitonin gene-related peptide (CGRP) or its receptor, namely gepants and monoclonal antibodies (3). This evidence concerns the gene CALCA and migraine disorder.